Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043).

Journal: Journal of acquired immune deficiency syndromes (1999)

Volume: 74

Issue: 2

Year of Publication: 2017

Affiliated Institutions:  *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Department of Probability and Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic; ‡Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD; §Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ‖Program in Global Health, University of California at Los Angeles, Los Angeles, CA; ¶Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; #Department of Global Health, University of Washington, Seattle, WA; **Muhimbili University of Health and Allied Sciences, Muhimbili University Teaching Hospital, Dar es Salaam, Tanzania; ††DST-NRF Centre of Excellence in Human Development, University of the Witwatersrand, Johannesburg, South Africa; ‡‡Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, South Africa; §§South African Medical Research Council, Cape Town, South Africa; ‖‖Department of Psychiatry and Behavioral Sciences, The Medical University of South Carolina, Charleston, SC; and ¶¶Center for World Health, David Geffen School of Medicine and UCLA Health, Los Angeles, CA.

Abstract summary 

Antiretroviral (ARV) drug treatment benefits the treated individual and can prevent HIV transmission. We assessed ARV drug use in a community-randomized trial that evaluated the impact of behavioral interventions on HIV incidence.Samples were collected in a cross-sectional survey after a 3-year intervention period. ARV drug testing was performed using samples from HIV-infected adults at 4 study sites (Zimbabwe; Tanzania; KwaZulu-Natal and Soweto, South Africa; survey period 2009-2011) using an assay that detects 20 ARV drugs (6 nucleoside/nucleotide reverse transcriptase inhibitors, 3 nonnucleoside reverse transcriptase inhibitors, and 9 protease inhibitors; maraviroc; raltegravir).ARV drugs were detected in 2011 (27.4%) of 7347 samples; 88.1% had 1 nonnucleoside reverse transcriptase inhibitors ± 1-2 nucleoside/nucleotide reverse transcriptase inhibitors. ARV drug detection was associated with sex (women>men), pregnancy, older age (>24 years), and study site (P < 0.0001 for all 4 variables). ARV drugs were also more frequently detected in adults who were widowed (P = 0.006) or unemployed (P = 0.02). ARV drug use was more frequent in intervention versus control communities early in the survey (P = 0.01), with a significant increase in control (P = 0.004) but not in intervention communities during the survey period. In KwaZulu-Natal, a 1% increase in ARV drug use was associated with a 0.14% absolute decrease in HIV incidence (P = 0.018).This study used an objective, biomedical approach to assess ARV drug use on a population level. This analysis identified factors associated with ARV drug use and provided information on ARV drug use over time. ARV drug use was associated with lower HIV incidence at 1 study site.

Authors & Co-authors:  Fogel Jessica M JM Clarke William W Kulich Michal M Piwowar-Manning Estelle E Breaud Autumn A Olson Matthew T MT Marzinke Mark A MA Laeyendecker Oliver O Fiamma Agnès A Donnell Deborah D Mbwambo Jessie K K JK Richter Linda L Gray Glenda G Sweat Michael M Coates Thomas J TJ Eshleman Susan H SH Chingono Alfred H AH

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378–384.
Authors :  17
Identifiers
Doi : 10.1097/QAI.0000000000001229
SSN : 1944-7884
Study Population
Male,Female
Mesh Terms
Adolescent
Other Terms
Study Design
Case Control Trial,Cross Sectional Study
Study Approach
Country of Study
Tanzania
Publication Country
United States